.png "Maureen McMahon, MD, MS photo")
Maureen McMahon, MD, MS
Professor of Rheumatology
UCLA David Geffen School of Medicine
Los Angeles, CA, United States
Disclosure(s): Astra Zeneca: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Aurinia: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Consultant (Ongoing); Glaxo Smith Kline: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
.png "Maria Dall'Era, MD photo")
Maria Dall'Era, MD
Director
UCSF
Corte Madera, CA, United States
Disclosure(s): Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Terminated, May 1, 2022); Aurinia: Consultant (Ongoing); BMS: Consultant (Ongoing); GlaxoSmithKline (GSK): Consultant (Ongoing)
Kenneth Kalunian, MD, FACR
UC San Diego
La Jolla, CA, United States
Disclosure information not submitted.
For nearly 50 years, therapeutic options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have been limited. Oral corticosteroids and immunosuppressant medications were often first-line therapies, as reflected in current treatment paradigms. However, these medications are associated with incomplete efficacy and substantial toxicity profiles, adding to the disease burden many patients faced often after a delayed diagnosis. However, the complex pathophysiology of these autoimmune diseases offers treatable targets for biologic agents. Since 2011, the FDA has approved several agents for the treatment of active, autoantibody-positive SLE, active LN, and moderate to severe SLE, but the relative newness of these agents accompanied by treatment paradigms that focus on older therapies present challenges when selecting appropriate regimens for individual patients. Further, estimates show that these autoimmune diseases disproportionately affect people of color, underscoring the need for culturally competent care. In this PeerView Live symposium, an expert panel will examine the latest evidence for currently approved targeted agents offering personal anecdotes and reflections to illustrate how scientific findings can inform everyday clinical practices and guide individualized approaches to care. Additionally, the panel will discuss the need for culturally competent care to ameliorate healthcare disparities offering evidence-based tools and tactics to overcome barriers and improve access to care and health information needs for patients of color.
Developed and offered by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education and supported by an educational grant from GlaxoSmithKline.
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS). Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
